MedTrace Logo

Resistance to Immunotherapy in Gastric Cancer

NCT03614013 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2018-08-06

No results posted yet for this study

Summary

This project seeks to analyze and define the mechanism (s) involved in the resistance to checkpoint therapy in metastatic GC patients. The investigators propose the use of a Next-Generation Sequencing (NGS) assay that involves 395 genes allowing us to define a specific molecular signature to characterize responder and non-responder patients to checkpoint therapy in combination with IHC analyses of specific factors. Such signature (s) could then be used to predict which individuals who might get the most benefit out of checkpoint therapy treatment. Analysis will be perfomed retrospectively using biopsies provided by mGC patients recruited at the Red de Salud UC treated with checkpoint therapy, the response of patients to treatment is evaluated by RECIST 1.1 criteria and thereby they are classified as "responders" or "non-responders".

Conditions

  • Metastatic Gastric Cancer

Interventions

OTHER

Immunotherapy responders/non-responders

paraffin samples will be collected retrospectively along with clinical data

Sponsors & Collaborators

  • Fondo Nacional de Desarrollo Científico y Tecnológico, Chile

    collaborator OTHER_GOV

  • Pontificia Universidad Catolica de Chile

    lead OTHER

Principal Investigators

  • Marcelo Garrido, MD · Pontificia Universidad Catolica de Chile

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-04
Primary Completion
2020-06-30
Completion
2021-03-31

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03614013 on ClinicalTrials.gov